The global Endobronchial Ultrasound Biopsy Market is estimated to be valued at Us$ 577 Mn in 2022 and is expected to exhibit a CAGR Of 4.6% over the forecast period 2017-2025, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Endobronchial ultrasound biopsy helps obtain tissue samples from lung nodules and lymph nodes through minimally invasive procedures. It has advantages over conventional biopsy methods by providing real-time images to guide the procedure and obtain samples without significant complications. The procedure is needed to diagnose lung tumors and other lung conditions at an early stage.
Market key trends:
The increasing demand for minimally invasive procedures in lung cancer diagnosis is driving the adoption of endobronchial ultrasound biopsy. The procedure takes less time compared to open lung biopsy and allows obtaining clear biopsy samples with real-time ultrasound navigation. It has led to reduced risk of complications and faster recovery time for patients. Growing incidence of lung cancer and new product launches with advanced features are expected to push the uptake of endobronchial ultrasound biopsy in the coming years.
Segment Analysis
The global endobronchial ultrasound biopsy market is segmented on the basis of product type, application, end user, and geography. By product type, the market is classified into bronchoscopes, ultrasound bronchoscopy probes, needles, and others. Among these, the bronchoscopes segment dominates the market due to increasing demand for endobronchial ultrasound procedures in the diagnosis and treatment of lung cancer and its ability to identify mediastinal lymph nodes.
Key Takeaways
The global Endobronchial Ultrasound Biopsy Market is expected to witness high growth, exhibiting a CAGR of 4.6% over the forecast period, due to increasing incidence of lung cancer. Regionally, North America is expected to be the fastest growing as well as the dominating regional market, due to rising lung cancer cases and presence of major players in the region.
The global endobronchial ultrasound biopsy market size was valued at US$ 469.5 Mn in 2016 and is expected to reach US$ 686.0 Mn by 2025. The increasing incidence of lung cancer is a major driver boosting the demand for endobronchial ultrasound biopsy procedures. According to the American Cancer Society, lung cancer is the second most common type of cancer worldwide.
By region, North America dominates the global market accounting for over 40% market share in 2025. Factors such as rapidly aging population, rising healthcare expenditure, availability of reimbursements, and presence of key players in the region are supporting the market growth. Asia Pacific is expected to witness the highest CAGR over the forecast period owing to increasing patient pool, growing healthcare sector, and rising disposable incomes.
Key players operating in the endobronchial ultrasound biopsy market are Boston Scientific Corporation, Medtronic PLC, Olympus Corporation, Cook Medical Incorporated, Veran Medical Technologies, Medi-Globe Corporation, Pentax Medical, FUJIFILM Corporation, and Simbionix USA Corporation. These players are focusing on new product launches, partnerships and acquisitions to gain market share. For instance, in September 2017, Olympus Corporation launched Olympus Exera II bronchovideoscope to enhance endobronchial ultrasound procedures.
Endobronchial valves were developed primarily by the start-up medical device company Emphasys Medical (now Pulmonx - Redwood City, California) as a minimally invasive alternative to lung volume reduction surgery for emphysema.
In lung volume reduction surgery, a surgeon cuts into a patient's chest and cuts out one or more diseased portion(s) of a lung.
Endobronchial valves were designed to replicate the effects of that procedure without requiring incisions, by simply allowing the most diseased portions of the lung to collapse.
Emphasys was purchased by Pulmonx in 2009Chronic obstructive pulmonary disease (COPD) is a widespread, progressive lung disease for The global endobronchial valves market which pulmonologists in the US have had few new treatment options available outside the standard pharmacological therapies, lung rehabilitation and high-risk lung volume reduction surgery.
Now emerging technologies, in particular, endobronchial valves, which aim to shrink hyperinflated lungs in severe emphysema patients, could soon become the first minimally invasive treatment option available in the US.The major factor expected to drive the growth of the endobronchial valves market is growing awareness regarding procedure for bronchoscopic lung volume reduction in various lung-related diseases.
The increasing prevalence of tobacco smoking worldwide is consequently expected to contribute to the growth of the endobronchial valves market.
